- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.

$AVXL amazing avxl still in singke digits after a supposedly amazing “pivotal” trial readout 🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

Sava has potential and the phase 3 results will show the truth.

watch $gns $slrx $nflx $hlbz LONG AND STRONG $VTVT *News about the start of TTP399 phase 3 any day from now When it finally happens after many years the stock will skyrocket

$SLRX SP-3164 showed significant tumor growth "inhibition" in in vivo studies including statistically significant improvement over the approved immunomodulatory drugs lenalidomide (Revlimid®) and pomalidomide (Pomalyst®)

Monday morning pre-market screamer 😱 candidates: 🚨🚨🚨💎💎💎🔥🔥🔥 $TCBP Phase 2 update still pending-huge potential on this nano float $BOXD over $1 easy $ALLR PT $.50 $HTGM she’s ready for another big run This week was very good to me.

SIMILAR SETUP TO $AMAM, $HTGM, $APVO, $APCX Volume increasing since last week ✅ Low float recent IPO ✅ Strong future trial pipeline ✅ Time for the next leg up towards IPO price!

SHOULD be some awesome opportunities this week, study study study!

$ATNM positive news in their acute myeloid leukemia trials 👇🏼 53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches It's time to get in before we blast off to $12+ next!